David MacDonald

Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study

Ian W. Flinn, Richard van der Jagt, Brad S. Kahl et al. · Blood · 2014 · 638 citations · Full text

Life Sciences, Immunology, Internal Medicine +3

Randomized Comparison of Gemcitabine, Dexamethasone, and Cisplatin Versus Dexamethasone, Cytarabine, and Cisplatin Chemotherapy Before Autologous Stem-Cell Transplantation for Relapsed and Refractory Aggressive Lymphomas: NCIC-CTG LY.12

Michael Crump, John Kuruvilla, Stephen Couban et al. · Journal of Clinical Oncology · 2014 · 463 citations · Full text

Medicine, Oncology, Pharmacology +14

Nonunion of the femoral diaphysis

P.V. Giannoudis, David MacDonald, S. J. Matthews et al. · Journal of Bone and Joint Surgery - British Volume · 2000 · 357 citations

Medicine, Orthopaedic Surgery, Orthopedic Surgery +11

First-Line Treatment of Patients With Indolent Non-Hodgkin Lymphoma or Mantle-Cell Lymphoma With Bendamustine Plus Rituximab Versus R-CHOP or R-CVP: Results of the BRIGHT 5-Year Follow-Up Study

Ian W. Flinn, Richard van der Jagt, Brad S. Kahl et al. · Journal of Clinical Oncology · 2019 · 307 citations · Full text

Medicine, Oncology, Pharmacotherapy +12

Genetic Landscapes of Relapsed and Refractory Diffuse Large B-Cell Lymphomas

Ryan D. Morin, Sarit Assouline, Miguel Alcaide et al. · Clinical Cancer Research · 2015 · 227 citations

Life Sciences, Genetics, Molecular Genetics +14